Literature DB >> 19188822

Metastatic HPV-related cervical adenocarcinomas presenting with thromboembolic events (Trousseau Syndrome): clinicopathologic characteristics of 2 cases.

Emanuela Veras1, Monica Srodon, Eric S Neijstrom, Brigitte M Ronnett.   

Abstract

Two cases of systemic thromboembolism (Trousseau syndrome) associated with metastatic human papillomavirus (HPV)-related endocervical adenocarcinomas are reported. The first patient, age 36, presented with bilateral lower extremity deep vein thromboses, pulmonary embolism, and supraclavicular and cervical lymphadenopathy. Lymph node biopsy revealed metastatic mucinous adenocarcinoma with focal signet ring cell differentiation. Imaging studies demonstrated metastatic disease without a defined primary site. Acute renal and respiratory failure developed and the patient expired shortly after initiation of chemotherapy, 7 weeks after presentation. Autopsy examination revealed widespread metastatic adenocarcinoma with a 2 cm cervical adenocarcinoma. The second patient, age 43, presented with left internal jugular vein thrombosis, acute thrombophlebitis, and bilateral axillary lymphadenopathy. She developed progressive venous thrombosis despite anticoagulation. Imaging studies demonstrated widespread lymphadenopathy and an adnexal mass. Diagnostic laparoscopy with biopsies and left oophorectomy revealed metastatic mucinous adenocarcinoma with signet ring cell differentiation involving peritoneum, ovary, cervix, and bladder without a defined primary site. Progressive thromboembolic disease with acute renal failure and multiple cerebral infarcts developed and the patient expired shortly after initiation of chemotherapy, 2 months after presentation. No autopsy was performed. HPV DNA was detected by in situ hybridization in the lymph node metastasis in the first case and in the cervical and ovarian tumor specimens in the second case. High-risk HPV-related endocervical adenocarcinomas occasionally exhibit signet ring cell differentiation and can present with Trousseau syndrome. These features more commonly suggest metastatic adenocarcinoma of upper gastrointestinal tract origin but the presence of HPV DNA within the tumors establishes them as cervical in origin.

Entities:  

Mesh:

Year:  2009        PMID: 19188822     DOI: 10.1097/PGP.0b013e318186a83b

Source DB:  PubMed          Journal:  Int J Gynecol Pathol        ISSN: 0277-1691            Impact factor:   2.762


  5 in total

1.  Primary signet ring cell carcinoma of the uterine cervix: A case report.

Authors:  Yeon Hee Kim; Su Jeong Lee; Seon Ui Lee; In Sun Hwang; Kwang Il Yim; Jin Hwi Kim
Journal:  Medicine (Baltimore)       Date:  2021-08-06       Impact factor: 1.817

2.  Expression of tissue factor in adenocarcinoma and squamous cell carcinoma of the uterine cervix: implications for immunotherapy with hI-con1, a factor VII-IgGFc chimeric protein targeting tissue factor.

Authors:  Emiliano Cocco; Joyce Varughese; Natalia Buza; Stefania Bellone; Michelle Glasgow; Marta Bellone; Paola Todeschini; Luisa Carrara; Dan-Arin Silasi; Masoud Azodi; Peter E Schwartz; Thomas J Rutherford; Sergio Pecorelli; Charles J Lockwood; Alessandro D Santin
Journal:  BMC Cancer       Date:  2011-06-22       Impact factor: 4.430

Review 3.  A new case of primary signet-ring cell carcinoma of the cervix with prominent endometrial and myometrial involvement: Immunohistochemical and molecular studies and review of the literature.

Authors:  Giovanna Giordano; Silvia Pizzi; Roberto Berretta; Tiziana D'Adda
Journal:  World J Surg Oncol       Date:  2012-01-11       Impact factor: 2.754

4.  Primary signet ring cell carcinoma of the cervix: A case report and review of the literature.

Authors:  Veysel Sal; Ilker Kahramanoglu; Hasan Turan; Nedim Tokgozoglu; Tugan Bese; Ovgu Aydin; Fuat Demirkiran; Macit Arvas
Journal:  Int J Surg Case Rep       Date:  2016-02-06

5.  A Rare Case of Primary Signet-Ring Cell Cervical Carcinoma: Early Stage with Independent Bilateral Ovarian Metastases.

Authors:  Shiyun Li; Fuqiang Gan; Manling Luo; Puying Luo
Journal:  Onco Targets Ther       Date:  2021-03-23       Impact factor: 4.147

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.